AMO959

PreclinicalSmall molecule

AMO959 is one of 3 small molecule programs targeting PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PSMA-Positive Metastatic Castration Resistant Prostate Cancer (mcrpc) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-Based ChemotherapyRecruiting

PSMA-Positive Metastatic Castration Resistant Prostate Cancer (mcrpc) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-Based ChemotherapyPreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in PSMA-Positive Metastatic Castration Resistant Prostate Cancer (mcrpc) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-Based Chemotherapy

#DrugCompanyPhaseTrials

Xtandi

Astellas

Preclinical

1 2

Zytiga

Johnson & Johnson

Preclinical

1 3

AMO959

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

PreclinicalRecruiting

PSMA-Positive Metastatic Castration Resistant Prostate Cancer (mcrpc) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-Based Chemotherapy

NCT07226986

Clinical

Trials by Indication[1]

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy1 trial

A Phase Ib/II Open-label, Multi-center Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With an Androgen Receptor Pathway Inhibitor (ARPI) in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC)

Recruiting· Novartis logo

Novartis·Preclinical·NCT07226986·123 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AMO959. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AMO959 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AMO959. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Novartis

AMO959

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy1 trial

References

Drug Info

Quick Facts

Related News